Which Phase I consideration relates to clearance and potential drug-drug interactions?

• A. Assessing manufacturing cost
• B. Monitoring post-marketing safety
• C. Assessing clearance and potential drug-drug interactions
• D. Marketing strategy planning

Answer: (C)

Phase I trials focus on pharmacokinetics and safety, specifically how the body handles a drug and how other drugs might influence that process. Clearance describes how quickly the body eliminates the drug, which helps determine dosing and frequency, while assessing potential drug-drug interactions looks at whether concomitant medications could inhibit or induce metabolic pathways (like certain liver enzymes or transporters) and thereby alter drug exposure or risk of adverse effects. This combination is essential in Phase I to set up safe dosing strategies and identify interactions early. The other options relate to manufacturing feasibility, post-marketing safety (Phase IV), or marketing activities, which are not the Phase I pharmacokinetic/dynamic focus.